This page shows what was measured, who it was measured in, and what that does not settle.
What Bortezomib does in the body
Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell.
From the FDA-approved label: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro .
Why people take it. The treatment of adult patients with multiple myeloma
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 69G8BD63PP · read 2026-08-29
Its recorded molecular formula is C19H25BN4O4, weighing 384.24.
US prescribing information · 854be921-5fd9-482a-8432-a0c0241625f8 · read 2026-08-30
Where each sentence above came from
A person wrote this explanation into the record, with the studies named in the path below.
The recorded use, written for a reader without medical training. Not signed off.
No statement of the main limit is recorded.
The four opening statements run to 117 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Event-free survival
✗ The study did not show it
Who was studied
NCT03643276
How many people
5000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous, subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Overall survival
✗ The study did not show it
Who was studied
NCT01554852
How many people
4420
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous, subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Event-free survival
✗ The study did not show it
Who was studied
NCT03390387
How many people
4000
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous, subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
16 weeks clinical response
✗ The study did not show it
Who was studied
NCT04817956
How many people
3000
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous, subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Event-free survival (EFS) in patients with newly diagnosed T-cell lymphoblastic leukemia (T-ALL)
✗ The study did not show it
Who was studied
NCT07072585
How many people
1708
Study design
Phase 2/Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous, subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations
✗ The study did not show it
Who was studied
NCT01371981
How many people
1645
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous, subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Bortezomib for injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma Bortezomib for injection, 3.5 mg/vial is indicated for the treatment of adult patients with multiple myeloma.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness have not been established in pediatric patients.”
US prescribing information · 854be921-5fd9-482a-8432-a0c0241625f8 · read 2026-08-30
On older people, the label states: “Of the 669 patients enrolled in the relapsed multiple myeloma study, 245 (37%) were 65 years of age or older: 125 (38%) on the bortezomib arm and 120 (36%) on the dexamethasone arm.”
US prescribing information · 854be921-5fd9-482a-8432-a0c0241625f8 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Based on its mechanism of action [see Clinical Pharmacology (12.1) ] and findings in animals, bortezomib can cause fetal harm when administered to a pregnant woman.”
US prescribing information · 854be921-5fd9-482a-8432-a0c0241625f8 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There are no data on the presence of bortezomib or its metabolites in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production.”
US prescribing information · 854be921-5fd9-482a-8432-a0c0241625f8 · read 2026-08-30
On people with reduced liver function, the label states: “No starting dosage adjustment of bortezomib is recommended for patients with mild hepatic impairment (total bilirubin ≤1× ULN and AST >ULN, or total bilirubin >1 to 1.5× ULN and any AST).”
US prescribing information · 854be921-5fd9-482a-8432-a0c0241625f8 · read 2026-08-30
On people with reduced kidney function, the label states: “No starting dosage adjustment of bortezomib is recommended for patients with renal impairment.”
US prescribing information · 854be921-5fd9-482a-8432-a0c0241625f8 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Given by a clinician
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Intravenous, subcutaneous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S3, S4.
No source is stored against this line.
What is in the pack
Sold as injectable, solution, powder, injection, powder, lyophilized, for solution, given by the intravenous, subcutaneous, injection, intravenous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Intravenous, subcutaneous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
52 products list this as an active ingredient in the United States drug directory. 52 of them contain it and nothing else.
FDA National Drug Code directory · 72338-200 · read 2026-08-29
They are sold as injection, injection, powder, lyophilized, for solution and powder, taken intravenous and subcutaneous.
FDA National Drug Code directory · 72338-200 · read 2026-08-29
The regulator's established pharmacologic class for it is proteasome inhibitor [epc] and proteasome inhibitors [moa].
FDA National Drug Code directory · 72338-200 · read 2026-08-29
30 published labels name it as an active ingredient. 30 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 854be921-5fd9-482a-8432-a0c0241625f8 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 854be921-5fd9-482a-8432-a0c0241625f8 · read 2026-08-29
1 marketed supplement label lists this ingredient, classed as other combinations.
Those labels carry all other and structure/function claims. A claim of that kind is written by the manufacturer and is not assessed by any regulator, so its presence says nothing about whether it is true.
bortezomib is intravenous at 3 DOSAGE FORMS AND STRENGTHS For injection: Each single-dose vial of bortezomib for injection contains 3.5 mg of bortezomib as a sterile lyophilized white to off-white powder for reconstitution and withdrawal of the app…, recorded as fda label in effect 2021-11-22 in the United States.
US prescribing information · 854be921-5fd9-482a-8432-a0c0241625f8 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Bortezomib studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Bortezomib are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
29 documents were read for this substance.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
69G8BD63PP
RxNorm concept
402243
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S3, S4.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
30 approved applications cover products containing this substance. The earliest was NDA021602, approved 20030513 to TAKEDA PHARMS USA.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (11)
Q2
On the Bortezomib label: indicated for what?
"Bortezomib for Injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma. ( 1.1 ) treatment of adult patients with mantle cell lymphoma.": indications and usage on Bortezomib's label. DailyMed label · decb5d94-2ea2-48d8-b08b-3196b24c0ed3 · 2026-01-09
Q3
830 registered trials of Bortezomib — at which phases?
Registered studies posting no result
534 of 830
830 registered studies of Bortezomib: 498 phase2, 256 phase1, 112 phase3, 25 na or unstated, 20 phase4, 15 na, 6 early phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"Administratively complete."; 141 of 830 registered studies
Show the evidence
Trial
NCT00006773
terminated; "Administratively complete."
NCT00023881
terminated; "Lack of efficacy"
NCT00040768
terminated; "Administratively complete."
NCT00066625
terminated; "Administratively complete."
NCT00085410
terminated; "The trial was discontinued early due to no confirmed partial responses."
NCT00103376
terminated; "Low Accrual"
14 further recorded trials
NCT00106262
terminated; "Lack of accrual"
NCT00117351
terminated; "insufficient efficacy"
NCT00124579
terminated; "poor accrual"
NCT00128921
terminated; "study terminated due to low accrual"
NCT00136591
terminated; "An arm closed due to lack of efficacy"
NCT00183937
terminated; "Sponsor stopped study early."
NCT00200382
terminated; "The study did not achieve the statistical success to continue."
NCT00210392
terminated; "After IELSG25A study amendment, patients subject of the present study were eligible for inclusion in the IELSG25A study"
NCT00265928
terminated; "Withdrawn for poor accrual"
NCT00271804
terminated; "New study with lenalidomide pending"
NCT00290706
terminated; "Closed per Data Monitoring Committee due to lack of efficacy"
NCT00361088
terminated; "Initial Principal Investigator left Moffitt"
NCT00361621
terminated; "Closed due to slow accrual"
NCT00366106
terminated; "Study was closed to enrollment when it became clear that enrollment was too slow to complete full enrollment target within time frame allowed."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Bortezomib used Bortezomib 1.0mg/m^2 — over how long?
studies of Bortezomib used the recorded amount. ClinicalTrials.gov · 2026-09-01
8 recorded entries; human; also "Bortezomib 1.0mg/m^2", "Bortezomib 1.3mg/m^2", "Bortezomib 1.3 mg/m2"
Show the evidence
human
NCT00410423
Bortezomib 1.0mg/m^2
NCT00410423
Bortezomib 1.3mg/m^2
NCT00424840
Bortezomib 1.3 mg/m2
NCT00424840
Bortezomib 1.6 mg/m2
NCT00424840
Bortezomib 1.8 mg/m2
NCT00784823
Bortezomib 1 mg/m2
2 more recorded rows
humanNCT01633645
VELCADE 1 mg/m2 on days 1 and 8, of a 21-days treatment cycle for a maximum of 8 cycles
humanNCT04348006
Bortezomib 3.5 MG
recorded 2026-09-01 · last checked 2026-09-04
Q6
Bortezomib's half-life is 40 to 193 hours — which schedules were studied?
40 to 193 hours, the half-life Bortezomib's label states: "Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose." DailyMed label · decb5d94-2ea2-48d8-b08b-3196b24c0ed3 · 2026-01-09
Show the evidence
half lifepharmacokinetics
40 to 193 hours; Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.
metabolismpharmacokinetics
Metabolism Bortezomib is primarily oxidatively metabolized to several inactive metabolites in vitro via cytochrome P450 (CYP) enzymes 3A4, CYP2C19, and CYP1A2, and to a lesser extent by CYP2D6 and CYP2C9.
recorded 2026-01-09 · last checked 2026-09-04
Q7
Which running trial of Bortezomib could settle lifespan?
NCT02112916 measures Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients, reading out 2026-09-16.
42 open trials; n 847; "Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma"
Show the evidence
Trial
NCT02112916
"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma"; n 847; "Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients"; 2026-09-16
NCT05248633
"Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma"; n 220; "event-free survival"; 2026-10
NCT01208662
"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65"; n 729; "Median Progression-Free Survival (PFS)"; 2026-12
NCT03729804
"Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)"; n 250; "Number of Participants with progression free survival with the group taking KRd versus VRd after randomization"; 2026-12-28
NCT05736419
"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)"; n 24; "Number of participants with treatment related mortality/TRM or primary graft failure"; 2027-02-09
NCT04181827
"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma"; n 419; "Progression Free Survival (PFS)"; 2027-03-31
14 further recorded trials
NCT00644228
"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma"; n 525; "Progression-free Survival"; 2027-06-10
NCT03319667
"A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant"; n 475; "Progression free survival (PFS)"; 2027-06-30
NCT03004287
"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy"; n 50; "Measure the progression-free survival in patients with high risk multiple myeloma"; 2027-10
NCT06140966
"Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma"; n 54; "2-year progression-free survival"; 2027-10-20
NCT03763162
"Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma"; n 40; "Progression free survival (PFS)"; 2027-10-30
NCT06158841
"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma"; n 421; "Progression Free Survival (PFS)"; 2027-12
NCT06152575
"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)"; n 492; "Progression free survival per International Myeloma Working Group criteria"; 2027-12-30
NCT04566328
"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial"; n 1450; "Consolidation overall survival"; 2027-12-31
NCT04246047
"Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma"; n 494; "Progression-free Survival (PFS)"; 2028-06-30
NCT06868654
"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma"; n 72; "Progression-free Survival (PFS)"; 2028-06-30
NCT06868667
"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma"; n 24; "Progression-free Survival (PFS)"; 2028-06-30
NCT03643276
"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017"; n 5000; "Event-free survival"; 2028-07-14
NCT00734877
"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma"; n 382; "Progression-free survival rate"; 2028-09
NCT05083169
"A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma"; n 587; "Progression Free Survival (PFS)"; 2028-09-15
Q8
Which 202 trials of Bortezomib posted no result?
Posted no result
202 of 202 completed trials
Registrations
NCT00006098, NCT00006362, NCT00028639, NCT00027716, NCT00064012 and NCT00048230, and 196 more
Completion dates
oldest 2001-10; newest 2024-05-20
Show the evidence
Trial
NCT00006098
2001-10
NCT00006362
2003-08
NCT00028639
2003-11
NCT00027716
2004-05
NCT00064012
2004-07
NCT00048230
2004-12
14 further recorded trials
NCT00038571
2005-03
NCT00063726
2005-07
NCT00021216
2005-12
NCT00093028
2006-01
NCT00752518
2006-01
NCT00025376
2006-03
NCT00216697
2006-10
NCT00193232
2007-02
NCT00059618
2007-04
NCT00017199
2007-05
NCT00142129
2007-06
NCT00217503
2007-06
NCT00068289
2007-07
NCT00083460
2007-11
Q9
At the median, Bortezomib's trials enrolled 39 people — anything larger?
Median enrolment
39
Largest enrolment
5000
Registered trials counted
808
Q10
What do 11074 spontaneous reports say about Bortezomib — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Bortezomib appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 11074 reaction mentions were counted: neuropathy peripheral 2710; plasma cell myeloma 2222; thrombocytopenia 1429; pneumonia 1133. FAERS via Open Targets · CHEMBL325041 · 2026-06-24
Show the evidence
neuropathy peripheral
2710
plasma cell myeloma
2222
thrombocytopenia
1429
pneumonia
1133
neutropenia
913
platelet count decreased
751
4 more recorded rows
disease progression
683
febrile neutropenia
553
polyneuropathy
384
plasma cell myeloma recurrent
296
recorded 2026-06-24 · last checked 2026-09-04
Q11
Which 10 reactions does Bortezomib's label not list?
( 7.1 ) 7.1 Effects of Other Drugs on Bortezomib for Injection Strong CYP3A4 Inducers Coadministration with a strong CYP3A4 inducer decreases the exposure of bortezomib [see Clinical Pharmacology ( 12.3 )] which may decrease Bortezomib for Injection efficacy.
drug_interactions
Avoid coadministration with strong CYP3A4 inducers.
drug_interactions
Strong CYP3A4 Inhibitors Coadministration with a strong CYP3A4 inhibitor increases the exposure of bortezomib [see Clinical Pharmacology ( 12.3 )] which may increase the risk of bortezomib toxicities.
drug_interactions
Monitor patients for signs of bortezomib toxicity and consider a bortezomib dose reduction if bortezomib must be given in combination with strong CYP3A4 inhibitors.
2 more recorded rows
Interaction statementpharmacokinetics
Metabolism Bortezomib is primarily oxidatively metabolized to several inactive metabolites in vitro via cytochrome P450 (CYP) enzymes 3A4, CYP2C19, and CYP1A2, and to a lesser extent by CYP2D6 and CYP2C9.
Interaction statementpharmacokinetics
Drug Interaction Studies Clinical Studies No clinically significant differences in bortezomib pharmacokinetics were observed when coadministered with dexamethasone (weak CYP3A4 inducer), omeprazole (strong CYP2C19 inhibitor), or melphalan in combination with prednisone.
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 6 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.